Review of therapeutic options and the management of patients with myelodysplastic syndromes

被引：1

作者：

Ozcan, Mehmet A. ^{[1
]}

Ilhan, Osman ^{[2
]}

Ozcebe, Osman I. ^{[3
]}

Nalcaci, Meliha ^{[4
]}

Gulbas, Zafer ^{[5
]}

机构：

[1] Dokuz Eylul Univ, Dept Hematol, Izmir, Turkey

[2] Ankara Univ, Sch Med, Dept Hematol, TR-06100 Ankara, Turkey

[3] Hacettepe Univ, Sch Med, Dept Hematol, Ankara, Turkey

[4] Istanbul Univ, Istanbul Fac Med, Dept Hematol, Istanbul, Turkey

[5] Anadolu Med Ctr, Dept Hematol, Kocaeli, Turkey

来源：

EXPERT REVIEW OF HEMATOLOGY | 2013年 / 6卷 / 02期

关键词：

chelation; cytogenetic aberrations; hematopoietic stem cell transplantation; immunomodulating therapy; immunosuppressive therapy; International Prognostic Scoring System; International Working Group for Prognosis in MDS; iron overload; myelodysplastic syndromes; transfusion therapy; STEM-CELL TRANSPLANTATION; IRON CHELATION-THERAPY; QUALITY-OF-LIFE; ACUTE MYELOGENOUS LEUKEMIA; TRANSFUSION-DEPENDENT PATIENTS; PROGNOSTIC SCORING SYSTEM; WORLD-HEALTH-ORGANIZATION; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; LONG-TERM SURVIVORS;

D O I：

10.1586/EHM.13.7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Myelodysplastic syndromes (MDS) are a poorly understood group of disorders caused by one or more genetic aberrations in the bone marrow-derived cell line responsible for hematopoiesis. Recent advances in genetic medicine have offered new insights into the epigenesis as well as the prognosis of MDS, but have not resulted in new or improved curative treatment options. Bone marrow transplantation, introduced before the advent of genetic medicine, is still the only potential cure. Advances in other medical and pharmaceutical areas have broadened the scope of supportive care and disease-modifying therapies, and treating physicians now have a broad range of disease management options depending on a patient's likely prognosis. There is now clear evidence that appropriate supportive care and therapeutic intervention can improve progression-free and overall survival of MDS patients.

引用

页码：165 / 189

页数：25

共 239 条

[71] Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload [J].